Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) was historically viewed as chemotherapy-insensitive.
• Estramustine phosphate, mitoxantrone, and docetaxel have challenged this view.
• Docetaxel was the only agent to improve survival in CRPC until recently.

Purpose of the Study:

• To review the clinical development of cabazitaxel for CRPC.
• To examine the rationale for cabazitaxel's efficacy.
• To discuss future therapeutic investigations for CRPC.

Main Methods:

• Review of clinical trials and preclinical data for cabazitaxel.
• Analysis of cabazitaxel's mechanism of action, including its interaction with P-glycoprotein.
• Examination of survival data from studies involving cabazitaxel in docetaxel-refractory CRPC.

Main Results:

• Cabazitaxel demonstrated improved survival in patients with docetaxel-refractory CRPC.
• Cabazitaxel is a novel taxane with reduced affinity for P-glycoprotein, a key drug efflux pump.
• Cabazitaxel has received regulatory approval for treating this patient population.

Conclusions:

• Cabazitaxel is the first cytotoxic agent to show survival benefit in docetaxel-refractory CRPC.
• Cabazitaxel offers a new standard of care for men with disease progression on docetaxel.
• Further research will explore optimal use and combination therapies involving cabazitaxel.